Evidence map›Paper›PMID 16968411›Full record

ArticleClinical and experimental immunology2006

Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo.

K Menzel, M Hausmann, F Obermeier, K Schreiter, N Dunger, F Bataille, W Falk, J Scholmerich, H Herfarth, G Rogler

Open access · greenAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 129 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Faecal Cathepsin B and S Are Associated With Liver Disease Severity and Adiposity in MASLD.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  5. Article
  6. Article
  7. Proteases in intestinal health and disease.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  8. Article
  9. Molecular medicine reports · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Heliyon · 2024
    Article
  16. Article
  17. Article
  18. Frontiers in immunology · 2024
    Article
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

K MenzelDepartment of Internal Medicine I, University of Regensburg, Regensburg, Germany.
M Hausmann
F Obermeier
K Schreiter
N Dunger
F Bataille
W Falk
J Scholmerich
H Herfarth
G Rogler
University of Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cathepsins D (CTSD), B (CTSB) and L (CTSL) are important for the intracellular degradation of proteins. Increased cathepsin expression is associated with inflammatory diseases. We have shown previously an induction of CTSD expression in intestinal macrophages (IMAC) in inflamed mucosa of patients with inflammatory bowel disease (IBD). Here we investigated the regulation of CTSB and CTSL in IMAC during IBD and effects of CTSD and CTSB/CTSL inhibition in vivo. Human IMAC were isolated from normal and inflamed mucosa. Reverse transcription-polymerase chain reaction (RT-PCR) was performed for CTSB and CTSL mRNA. Immunostaining was used to confirm PCR results. Cathepsin inhibition was investigated in the dextran-sulphate-sodium (DSS) colitis model in mice with application of pepstatin A (CTSD inhibitor), CA-074 (CTSB inhibitor) and Z-Phe-Tyr-aldehyde (CTSL inhibitor). CTSL mRNA was significantly up-regulated in IMAC isolated from IBD mucosa. Up-regulated protein expression was found mainly in areas of mucosal damage by immunostaining. Inhibition of CTSD in mouse DSS colitis was followed by an amelioration of the disease. Inhibitor-treated mice showed a significant lower histological score (HS) and less colon reduction in comparison to controls. Similarly, simultaneous inhibition of CTSB/CTSL was followed by a significant amelioration of colitis. Expression of tissue-degrading cathepsins is increased in IMAC in IBD. Inhibition of CTSD as well as CTSB/CTSL is followed by an amelioration of experimental colitis. The prevention of mucosal damage by cathepsin inhibition could represent a new approach for the therapy of IBD.

Indexed as

AnimalsCathepsin BCathepsin DCathepsin LCathepsinsColitisCysteine EndopeptidasesCysteine Proteinase InhibitorsDipeptidesDisease Models, AnimalFemaleGene ExpressionHumansInflammatory Bowel DiseasesIntestinal MucosaMacrophagesCathepsin BCathepsin DCathepsin LCathepsinsCTSL protein, humanCtsl protein, mouseCysteine EndopeptidasesCysteine Proteinase InhibitorsDipeptidesN-(3-propylcarbamoyloxirane-2-carbonyl)-isoleucyl-prolineN-(benzyloxycarbonyl)-phenylalanyl-tyrosinalRNA, Messenger

Identifiers

PMID16968411
PMCPMC1809720
OpenAlexW2052463634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.